Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis

The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interp...

Descripción completa

Detalles Bibliográficos
Autor principal: Dellinger, R Phillip
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550791/
https://www.ncbi.nlm.nih.gov/pubmed/16542472
http://dx.doi.org/10.1186/cc3991
_version_ 1782129274064470016
author Dellinger, R Phillip
author_facet Dellinger, R Phillip
author_sort Dellinger, R Phillip
collection PubMed
description The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interpretation. Additional studies of recombinant activated protein C (rhAPC) have added to our understanding about this drug and to controversy as well. So how do we deal with rhAPC use in our clinical practice?
format Text
id pubmed-1550791
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-15507912006-08-22 Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis Dellinger, R Phillip Crit Care Commentary The PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1% absolute decrease in mortality with a p value of 0.005. Despite the impressive results of this trial, criticism of the study has targeted various aspects of design, analysis and interpretation. Additional studies of recombinant activated protein C (rhAPC) have added to our understanding about this drug and to controversy as well. So how do we deal with rhAPC use in our clinical practice? BioMed Central 2006 2006-01-30 /pmc/articles/PMC1550791/ /pubmed/16542472 http://dx.doi.org/10.1186/cc3991 Text en Copyright © 2006 BioMed Central Ltd
spellingShingle Commentary
Dellinger, R Phillip
Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title_full Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title_fullStr Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title_full_unstemmed Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title_short Recombinant activated protein C: the key is clinical assessment of risk of death, not subset analysis
title_sort recombinant activated protein c: the key is clinical assessment of risk of death, not subset analysis
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1550791/
https://www.ncbi.nlm.nih.gov/pubmed/16542472
http://dx.doi.org/10.1186/cc3991
work_keys_str_mv AT dellingerrphillip recombinantactivatedproteincthekeyisclinicalassessmentofriskofdeathnotsubsetanalysis

Ejemplares similares